# NRG/GOG Foundation

# Uterine Corpus Subcommittee

Gynecologic Oncology Group

Gynecologic Oncology Group

NRG ONCOLOGY

*Advancing Research. Improving Lives.™*

GOG Foundation/Partners

Gynecologic Oncology Group

# Pelvic Recurrence

- 2/25/2008
- Endorsed by RTOG
- XX/154 accrued




Institution IMRT Credentialing is required when IMRT is to be used before registering any patient on this trial. A Knowledge Assessment for this study must be completed by the treating radiation oncologist before registering patients on this trial.

For patients with tumors involving the distal vagina and clinically negative groins, the bilateral inguino-femoral lymph node regions should be treated to 4500 cGy.

3-D conformal or IMRT boost is allowed for patients who are not candidates for brachytherapy.

# Leiomyosarcoma: Stage I



# GOG TRIALS IN DEVELOPMENT

- **UC 1306:** A randomized phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUS) after stabilization or response to chemotherapy following surgery or in metastatic first line treatment

Approved by CTEP

# EORTC 62113-55115 / GOG UC1306
# High Grade Undifferentiated Uterine Sarcoma




**International Rare Cancers Initiative**

# LOW-RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA




6/18/2012
XX/381 accrued
GCIG collaboration

Gynecologic Oncology Group